Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple blood protein boost stroke recovery?

NCT ID NCT07365475

Disease control Sponsor: Tianjin Huanhu Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests whether giving human albumin directly into the artery supplying the brain, right after a clot is removed, can improve recovery in people with severe stroke. About 306 participants will be randomly assigned to receive either standard clot removal alone or clot removal plus albumin. The goal is to see if albumin helps more patients regain independence three months later.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
human albumin (a protein in blood that may protect the brain)
What this could lead to
If it works, this could offer a simple add-on treatment to help more stroke survivors regain independence after clot removal.
What could go wrong
This is a Phase 2 trial, so it is still early. The benefit is uncertain, and there is a small risk of bleeding or allergic reaction from the albumin infusion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 306 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Acute anterior circulation large vessel occlusion (including ICA/MCA-M1 tandem occlusion or isolated MCA-M1 occlusion) confirmed by CTA, MRA, or DSA, with successful recanalization (eTICI score ≥2b) confirmed by the final intraoperative DSA following mechanical thrombectomy * Baseline NIHSS scores ≥ 6 * Non-contrast CT ASPECTS ≥6 * Time from stroke onset (or last known well) to arterial puncture within 24 hours * Pre-stroke functional independence, defined as a modified Rankin Scale (mRS) score \<2 * Written informed consent obtained from the patient or a legally authorized representative Exclusion Criteria: * Intracranial hemorrhage confirmed by cranial CT or MRI * Midline shift with significant mass effect on cranial CT or MRI * Isolated internal carotid artery (ICA) occlusion * History of heart failure or severe cardiovascular disease, including but not limited to pulmonary hypertension or pericardial effusion * Hemodynamically unstable arrhythmia (based on patient self-report or detected prior to infusion) * Symptoms or electrocardiographic evidence of acute myocardial infarction upon admission * Acute or chronic renal failure (serum creatinine \>2.0 mg/dL * Severe anemia (hematocrit \<32% * Known hypersensitivity to albumin or blood products * Pregnancy * Persistent hypertension (blood pressure ≥180/100mmHg) prior to albumin infusion * Current participation in other clinical trials * Life expectancy of less than 3 months * Concomitant severe pulmonary disease, such as chronic obstructive pulmonary disease, pulmonary fibrosis, pleural effusion, or acute respiratory distress syndrome * Any other condition that, in the opinion of the investigator, renders the patient unsuitable for participation in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute ischemic stroke due to anterior circulation large vessel occlusion are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cerebral artery occlusion ischemic stroke large artery stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute ischemic stroke from large vessel occlusion

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.